Clinical Trial Update: Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update on the safety and efficacy of T8 for chronic abnormal immune activation in HIV/AIDS patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Aids
• HIV Infection

Drugs mentioned

• T8

Snippet

Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Conditions: Chronic Abnormal Immune Activation in HIV/AIDS | Phase 2 | Status: COMPLETED